Souhaitez-vous accéder aux communiqués récents ?

NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third quarter ended September 30, 2015 and recent company...

Company to Host Third Quarter Earnings Conference Call to Review Financial Results, Business Updates as well as Provide an Overview of the ASH Abstract Data, on Monday November 9, 2015 at 8:30 am ET...

NEW YORK, Nov. 04, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, November 9, 2015 at 8:30am ET to discuss results for...

NEW YORK, Sept. 25, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will...

Novel Design Allows for Simultaneous Approval of Two Investigational Agents in a Single Phase 3 Study Under SPA Study Will Include Both Front-Line and Previously Treated Patients With CLL...

NEW YORK, Sept. 9, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the initiation of a Phase 1/2 clinical study that will investigate the use of TGR-1202, the Company's...

NEW YORK, Sept. 8, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences this month. Michael S. Weiss, the Company's...

NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 2015 and recent company...

NEW YORK, Aug. 5, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, August 10, 2015 at 8:30am ET to discuss results for the...

95% Overall Response Rate (ORR) in Patients with High-Risk CLL, the same patient population being studied in the Company's on-going Phase 3 GENUINE study being conducted under Special Protocol...